Kevin Lee: Bridging the Recognition Gap for ME/CFS Patients
Kevin Lee, Specialist physician (nuclear medicine and endocrinology) at Qscan Group, shared a post on LinkedIn:
“The Common Chronic Disease We Aren’t Talking About
As a physician who sees many patients referred for Long COVID and MECFS (Myalgic Encephalomyelitis), one of the most challenging aspects isn’t just the misdiagnosis or the delayed diagnosis – it’s the persistent misconception that this condition is rare.
Based on current estimates, there are potentially 900,000+ Australians living with an ME/CFS features since the pandemic began.
The Scale of the Challenge
If these estimates are correct, ME/CFS has surged into one of the most common chronic diseases in Australia:
- All Cancer Survivors (5-year): ~528,000 (ME/CFS is nearly double)
- Endometriosis: ~830,000–850,000 (ME/CFS has surpassed even this widespread condition)
- Rheumatoid Arthritis (RA): ~450,000 (ME/CFS is double)
- Stroke (Survivors): ~450,000 (ME/CFS is double)
- All forms of Dementia: ~433,000 (ME/CFS is double)
- Myocardial Infarction (Heart Attack Survivors): ~430,000 (ME/CFS is double)
- Inflammatory Bowel Disease (IBD): ~180,000 (ME/CFS is 5x more common)
- Type 1 Diabetes: ~120,000 (ME/CFS is 7.5x more common)
- Multiple Sclerosis (MS): ~38,000 (ME/CFS is roughly 23x more common)
- Lupus (SLE): ~20,000 (ME/CFS is roughly 45x more common)
- Motor Neuron Disease (People may remember the Ice Bucket challenge): ~2,800 (ME/CFS is over 300x more common)
Why this matters to us as Endocrinologists
While ME/CFS is a multi-systemic illness, these patients frequently present to endocrinologists with symptoms that mimic or overlap with primary hormonal dysfunction:
- HPA axis dysregulation, male hypogonadism, ‘flat’ cortisol profiles, low T3 syndrome.
- Dysmetabolism, weight gain/loss, bioenergetic dysfunction.
- Autonomic dysregulation and orthostatic intolerance (POTS).
The Recognition Gap
Despite being more prevalent than many conditions that have alot more funding, that have better access to hospitals, specialised clinics, and massive research budgets, ME/CFS remains disproportionally much much disadvantaged and under-recognised.
Patients are still fighting for:
Validation: Moving beyond the ‘it’s just fatigue’ stigma.
Clinical Infrastructure: Our current system is not built for a patient load of a million people.
Research Funding: We need the science to move from ‘diagnosis’ to ‘treatment.’
We can no longer treat ME/CFS as a ‘niche’ concern. It is a mainstream public health priority. As clinicians, we must bridge the gap between these statistics and the quality of care provided on the ground.”

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 14, 2026, 15:14This Month’s F and S On Air Podcast Is Out Now – Fertility and Sterility
-
Apr 14, 2026, 14:51Lydia Akpan: Key Signs of Oocyte Dysmorphism
-
Apr 14, 2026, 14:42Emre Göksan Pabuçcu: Honored to Speak at the 12th National Gynecological Endoscopy Congress
-
Apr 14, 2026, 14:36Shivam Rathore: Why Temperature and Humidity Control in IVF Labs is Non-Negotiable?
-
Apr 14, 2026, 14:29Yannick Hurni: Attending SEUD 2026 Has Been a Powerful Reminder of What Conferences Truly Represent
-
Apr 14, 2026, 14:26Maria Cristina Sangiovanni: Honored to Have Spoken at the 12th SEUD Congress in Frankfurt!
-
Apr 14, 2026, 14:21Nikolaos Polyzos: What Will Reproductive Medicine Look Like in 10 Years?
-
Apr 14, 2026, 14:16Xavier Carcopino: Early and Organized HPV Vaccination Saves Lives
-
Apr 14, 2026, 12:52Ting Yuan: Using Endometrial Immune Profiling in Young IVF Patients
